Incyte Corporation (LON:0J9P)
London · Delayed Price · Currency is GBP · Price in USD 90.63
-1.83 (-1.98%)
At close: Oct 29, 2025
Incyte Employees
Incyte had 2,617 employees as of December 31, 2024. The number of employees increased by 93 or 3.68% compared to the previous year.
Employees
2,617
Change (1Y)
93
Growth (1Y)
3.68%
Revenue / Employee
1.37M GBP
Profits / Employee
337.88K GBP
Market Cap
13.30B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2,617 | 93 | 3.68% |
| Dec 31, 2023 | 2,524 | 200 | 8.61% |
| Dec 31, 2022 | 2,324 | 230 | 10.98% |
| Dec 31, 2021 | 2,094 | 321 | 18.10% |
| Dec 31, 2020 | 1,773 | 317 | 21.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,349 |
| Spire Healthcare Group | 15,703 |
| ConvaTec Group | 10,489 |
| Hikma Pharmaceuticals | 9,500 |
| Genus | 3,190 |
Incyte News
- 3 days ago - Incyte and Enable Injections Announce Strategic Partnership for enFuse® On-Body Delivery System - Business Wire
- 5 days ago - Incyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura® (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis - Business Wire
- 6 days ago - Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial - PRNewsWire
- 8 days ago - Incyte: Strong Growth, Margin Expansion, And Low Valuation - Seeking Alpha
- 10 days ago - Incyte Corporation (INCY) Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic Cancer Transcript - Seeking Alpha
- 11 days ago - Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma - Business Wire
- 14 days ago - Notable Thursday Option Activity: PYPL, HPE, INCY - Nasdaq
- 15 days ago - 3 Biotech Stocks I Am Accumulating - Seeking Alpha